Use of Zoledronic Acid in the Treatment of Paget's Disease
| Title: | Use of Zoledronic Acid in the Treatment of Paget's Disease |
| Author: |
Seton, Margaret P.; Krane, Stephen Martin
Note: Order does not necessarily reflect citation order of authors. |
| Citation: | Seton, Margaret, and Stephen M. Krane. 2007. Use of zoledronic acid in the treatment of Paget's disease. Therapeutics and Clinical Risk Management 3(5): 913-918. |
| Full Text & Related Files: |
2376069.pdf (76.41Kb; PDF) 
|
| Abstract: | This review examines the use of zoledronic acid in the treatment of Paget’s disease of bone. It begins with a brief discussion of the theories of pathogenesis of Paget’s disease, its clinical manifestations, and the history of bisphosphonate treatment in this disorder. Risk of oversuppression of bone by the more potent bisphosphonates and their association with avascular necrosis of the jaw are noted. |
| Other Sources: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376069/pdf/ |
| Terms of Use: | This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
| Citable link to this page: | http://nrs.harvard.edu/urn-3:HUL.InstRepos:5310895 |
| Downloads of this work: |
This item appears in the following Collection(s)
-
HMS Scholarly Articles [16709]
Contact administrator regarding this item (to report mistakes or request changes)
